vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Paylocity Holding Corp (PCTY). Click either name above to swap in a different company.
Paylocity Holding Corp is the larger business by last-quarter revenue ($387.0M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). Paylocity Holding Corp runs the higher net margin — 13.0% vs 11.1%, a 1.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.3%). Paylocity Holding Corp produced more free cash flow last quarter ($113.6M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Paylocity Holding Corporation is an American provider of cloud-based payroll, , spend management, and human capital management (HCM) software.
ANIP vs PCTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $387.0M |
| Net Profit | $27.5M | $50.2M |
| Gross Margin | — | 72.9% |
| Operating Margin | 14.1% | 18.2% |
| Net Margin | 11.1% | 13.0% |
| Revenue YoY | 29.6% | 11.3% |
| Net Profit YoY | 367.5% | 34.0% |
| EPS (diluted) | $1.14 | $0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $387.0M | ||
| Q3 25 | $227.8M | $378.9M | ||
| Q2 25 | $211.4M | $369.9M | ||
| Q1 25 | $197.1M | $421.1M | ||
| Q4 24 | $190.6M | $347.7M | ||
| Q3 24 | $148.3M | $333.1M | ||
| Q2 24 | $138.0M | $324.7M | ||
| Q1 24 | $137.4M | $366.8M |
| Q4 25 | $27.5M | $50.2M | ||
| Q3 25 | $26.6M | $48.0M | ||
| Q2 25 | $8.5M | $48.6M | ||
| Q1 25 | $15.7M | $91.5M | ||
| Q4 24 | $-10.3M | $37.5M | ||
| Q3 24 | $-24.2M | $49.6M | ||
| Q2 24 | $-2.3M | $48.8M | ||
| Q1 24 | $18.2M | $85.3M |
| Q4 25 | — | 72.9% | ||
| Q3 25 | — | 73.9% | ||
| Q2 25 | — | 73.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 72.6% | ||
| Q3 24 | — | 74.4% | ||
| Q2 24 | — | 74.0% | ||
| Q1 24 | — | 77.8% |
| Q4 25 | 14.1% | 18.2% | ||
| Q3 25 | 15.9% | 19.6% | ||
| Q2 25 | 6.6% | 17.9% | ||
| Q1 25 | 13.3% | 30.2% | ||
| Q4 24 | -2.3% | 13.4% | ||
| Q3 24 | -13.8% | 19.3% | ||
| Q2 24 | 3.7% | 19.4% | ||
| Q1 24 | 14.8% | 29.0% |
| Q4 25 | 11.1% | 13.0% | ||
| Q3 25 | 11.7% | 12.7% | ||
| Q2 25 | 4.0% | 13.1% | ||
| Q1 25 | 8.0% | 21.7% | ||
| Q4 24 | -5.4% | 10.8% | ||
| Q3 24 | -16.3% | 14.9% | ||
| Q2 24 | -1.7% | 15.0% | ||
| Q1 24 | 13.2% | 23.3% |
| Q4 25 | $1.14 | $0.92 | ||
| Q3 25 | $1.13 | $0.86 | ||
| Q2 25 | $0.36 | $0.87 | ||
| Q1 25 | $0.69 | $1.61 | ||
| Q4 24 | $-0.45 | $0.66 | ||
| Q3 24 | $-1.27 | $0.88 | ||
| Q2 24 | $-0.14 | $0.85 | ||
| Q1 24 | $0.82 | $1.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $162.5M |
| Total DebtLower is stronger | — | $81.3M |
| Stockholders' EquityBook value | $540.7M | $1.1B |
| Total Assets | $1.4B | $7.0B |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $162.5M | ||
| Q3 25 | $262.6M | $165.2M | ||
| Q2 25 | $217.8M | $398.1M | ||
| Q1 25 | $149.8M | $477.8M | ||
| Q4 24 | $144.9M | $482.4M | ||
| Q3 24 | $145.0M | $778.5M | ||
| Q2 24 | $240.1M | $401.8M | ||
| Q1 24 | $228.6M | $492.7M |
| Q4 25 | — | $81.3M | ||
| Q3 25 | — | $81.3M | ||
| Q2 25 | — | $162.5M | ||
| Q1 25 | — | $243.8M | ||
| Q4 24 | — | $325.0M | ||
| Q3 24 | — | $325.0M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $1.2B | ||
| Q4 24 | $403.7M | $1.2B | ||
| Q3 24 | $405.9M | $1.1B | ||
| Q2 24 | $455.8M | $1.0B | ||
| Q1 24 | $452.0M | $1.1B |
| Q4 25 | $1.4B | $7.0B | ||
| Q3 25 | $1.4B | $4.2B | ||
| Q2 25 | $1.3B | $4.4B | ||
| Q1 25 | $1.3B | $5.2B | ||
| Q4 24 | $1.3B | $5.3B | ||
| Q3 24 | $1.3B | $4.0B | ||
| Q2 24 | $920.8M | $4.2B | ||
| Q1 24 | $914.5M | $5.0B |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $117.0M |
| Free Cash FlowOCF − Capex | $29.1M | $113.6M |
| FCF MarginFCF / Revenue | 11.8% | 29.4% |
| Capex IntensityCapex / Revenue | 0.5% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $461.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $117.0M | ||
| Q3 25 | $44.1M | $86.5M | ||
| Q2 25 | $75.8M | $86.6M | ||
| Q1 25 | $35.0M | $186.0M | ||
| Q4 24 | $15.9M | $54.2M | ||
| Q3 24 | $12.5M | $91.5M | ||
| Q2 24 | $17.4M | $79.9M | ||
| Q1 24 | $18.3M | $167.5M |
| Q4 25 | $29.1M | $113.6M | ||
| Q3 25 | $38.0M | $82.7M | ||
| Q2 25 | $71.8M | $81.1M | ||
| Q1 25 | $32.5M | $183.7M | ||
| Q4 24 | $13.5M | $51.2M | ||
| Q3 24 | $7.7M | $89.1M | ||
| Q2 24 | $13.0M | $73.6M | ||
| Q1 24 | $13.7M | $162.0M |
| Q4 25 | 11.8% | 29.4% | ||
| Q3 25 | 16.7% | 21.8% | ||
| Q2 25 | 34.0% | 21.9% | ||
| Q1 25 | 16.5% | 43.6% | ||
| Q4 24 | 7.1% | 14.7% | ||
| Q3 24 | 5.2% | 26.8% | ||
| Q2 24 | 9.4% | 22.7% | ||
| Q1 24 | 10.0% | 44.2% |
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 1.0% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 0.9% | ||
| Q3 24 | 3.2% | 0.7% | ||
| Q2 24 | 3.2% | 1.9% | ||
| Q1 24 | 3.3% | 1.5% |
| Q4 25 | 1.10× | 2.33× | ||
| Q3 25 | 1.66× | 1.80× | ||
| Q2 25 | 8.87× | 1.78× | ||
| Q1 25 | 2.23× | 2.03× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 1.84× | ||
| Q2 24 | — | 1.64× | ||
| Q1 24 | 1.00× | 1.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
